Citations

Showing 10 of 108152 citations.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Nakamura, Ryotaro , Saber, Wael , Martens, Michael J. , Ramirez, Alyssa, Scott, Bart L. , Oran, Betül , Leifer, Eric , Tamari, Roni , Mishra, Asmita , Maziarz, Richard T. , Westervelt, Peter, Vasu, Sumithira , Patnaik, Mrinal M. , Kamble, Rammurti T., Forman, Stephen J. , Appelbaum, Frederick R. , Mendizabal, Adam , Logan, Brent R. , Horowitz, Mary M. , Scott, Bart , McGuirk, Joseph , Patnaik, Mrinal , Sekeres, Mikkael A , Logan, Brent , Horowitz, Mary , Cutler, Corey S. , Maziarz, Richard Thomas , Martens, Michael J , Oran, Betul , McGuirk, Joseph P. , Sekeres, Mikkael A.

Mayo Clinic

Journal of Clinical Oncology | June 9, 2021 | Volume: 39 | Issue: 30 | Pages: 3328-3339

10.1200/jco.20.03380 | PMID 34106753 Get It

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. METHODS We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. RESULTS The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm ( P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free survival at 3 years was greater in the Donor arm (35.8%; 95% CI, 29.8 to 41.8) compared with the No-Donor arm (20.6%; 95% CI, 13.3 to 29.1; P = .003). The survival benefit was seen across all subgroups examined. CONCLUSION We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.
A Systematic Review and Meta-Analysis of Cell-Based Interventions in Experimental Diabetic Kidney Disease
Hickson, LaTonya J. , Abedalqader, Tala, Ben-Bernard, Gift, Mondy, Jayla , Bian, Xiaohui , Conley, Sabena M., Zhu, Xiangyang , Kukla, Aleksandra , Lorenz, Elizabeth C. , Lerman, Lilach O. , Mondy, Jayla M, Kim, Seo Rin , Thorsteinsdottir, Bjorg , Lerman, Lilach O , Hickson, LaTonya J , Abedalqader, Tala , Herrmann, Sandra M. , Murad, M. Hassan

Mayo Clinic

Stem Cells Translational Medicine | June 9, 2021 | Volume: 10 | Issue: 9 | Pages: 1304-1319

10.1002/sctm.19-0419 | PMID 34106528 Get It

AbstractRegenerative, cell-based therapy is a promising treatment option for diabetic kidney disease (DKD), which has no cure. To prepare for clinical translation, this systematic review and meta-analysis summarized the effect of cell-based interventions in DKD animal models and treatment-related factors modifying outcomes. Electronic databases were searched for original investigations applying cell-based therapy in diabetic animals with kidney endpoints (January 1998-May 2019). Weighted or standardized mean differences were estimated for kidney outcomes and pooled using random-effects models. Subgroup analyses tested treatment-related factor effects for outcomes (creatinine, urea, urine protein, fibrosis, and inflammation). In 40 studies (992 diabetic rodents), therapy included mesenchymal stem/stromal cells (MSC; 61%), umbilical cord/amniotic fluid cells (UC/AF; 15%), non-MSC (15%), and cell-derived products (13%). Tissue sources included bone marrow (BM; 65%), UC/AF (15%), adipose (9%), and others (11%). Cell-based therapy significantly improved kidney function while reducing injury markers (proteinuria, histology, fibrosis, inflammation, apoptosis, epithelial-mesenchymal-transition, oxidative stress). Preconditioning, xenotransplantation, and disease-source approaches were effective. MSC and UC/AF cells had greater effect on kidney function while cell products improved fibrosis. BM and UC/AF tissue sources more effectively improved kidney function and proteinuria vs adipose or other tissues. Cell dose, frequency, and administration route also imparted different benefits. In conclusion, cell-based interventions in diabetic animals improved kidney function and reduced injury with treatment-related factors modifying these effects. These findings may aid in development of optimal repair strategies through selective use of cells/products, tissue sources, and dose administrations to allow for successful adaptation of this novel therapeutic in human DKD.
Short‐ and mid‐term outcomes in percutaneous mitral valve replacement using balloon expandable valves
Eng, Marvin H. , Kargoli, Faraj , Wang, Dee Dee , Frisoli, Tiberio , Villablanca, Pedro, Nemeh, Hassan, Guerrero, Mayra , O’Neill, Brian , Wyman, Janet , Guerrero, Mayra E , O'Neill, Brian P , Wang, Dee Dee , Lee, James C. , Villablanca, Pedro, Greenbaum, Adam B. , O’Neill, William W.

Mayo Clinic

Catheterization and Cardiovascular Interventions | June 9, 2021 | Volume: 98 | Issue: 6 | Pages: 1193-1203

10.1002/ccd.29783 | PMID 34106514 Get It

AbstractBackgroundDue to elevated surgical risk, transcatheter mitral valve replacement (TMVR) is used as an alternative for treating failed bioprosthetic valves, annuloplasty repairs and mitral annular calcification (MAC). We report the procedural and longitudinal outcomes for each subtype: Mitral valve‐in‐valve (MVIV), mitral valve‐in‐ring (MViR), and valve‐in‐MAC (ViMAC).MethodsConsecutive patients undergoing TMVR from October 2013 to December 2019 were assessed. Patients at high risk for left ventricular outflow tract obstruction had either alcohol septal ablation or intentional laceration of the anterior leaflet (LAMPOON).ResultsEight‐eight patients underwent TMVR; 38 MViV, 31 MViR, and 19 ViMAC procedures were performed. The median Society of Thoracic Surgery 30‐day predicted risk of mortality was 8.2% (IQR 5.2, 19.9) for all. Sapien 3 (78%) and transseptal access (98%) were utilized in most cases. All‐cause in‐hospital mortality, technical, and procedural success were 8%, 83%, and 66% respectively. Median follow up was 1.4 years (IQR 0.5–2.9 years) and overall survival was 40% at 4 years. Differential survival rates were observed with MViV doing the best, followed by MViR and ViMAC having a <20% survival at 4 years. After adjusting for co‐variates, MViV procedure was the strongest predictor of survival (HR 0.24 [95% CI 0.079–0.7]).ConclusionTMVR is performed in at high‐risk patients with attenuated long‐term survival. MViV has the best success and survival rate, but long‐term survival in MViR and ViMAC is guarded.
Ocular Manifestations of Neuronal Ceroid Lipofuscinoses
Singh, Rohan Bir , Gupta, Prakash , Kartik, Akash , Farooqui, Naba , Singhal, Sachi , Shergill, Sukhman , Singh, Kanwar Partap , Agarwal, Mamta , Agarwal, Aniruddha

Mayo Clinic

Seminars in Ophthalmology | June 9, 2021 | Volume: 36 | Issue: 7 | Pages: 582-595

10.1080/08820538.2021.1936571 | PMID 34106804 Get It

Autologous Mesenchymal Stem Cell Therapy for Idiopathic Pulmonary Fibrosis and Comprehensive Assessment of Circulating Immune Populations Cells
Atanasova, Elena, Milosevic, Dragana , Bornschlegl, Svetlana, Krucker, Karen, Jacob, Eapen, Porquera, Eva Carmona, Anderson, Dagny, Egan, Ashley M. , Dietz, Allan B. , Carmona, Eva M. , Carmona, Eva M , Dietz, Allan B , Limper, Andrew H.

Mayo Clinic

No container title available | June 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-570630/v1 Get It

Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive pulmonary disease characterized by aberrant tissue remodeling, formation of scar tissue within the lungs and continuous loss of lung function. The areas of fibrosis seen in lungs of IPF patients share many features with normal aging lung with cellular senescence being one. The contribution of the immune system to the etiology of IPF remains poorly understood. Evidence obtained from animal models and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses. Currently, there is only modestly effective pharmacotherapy for IPF. Mesenchymal stem cells (MSCs)-based therapies have emerged as a potential option treatment of IPF. This study explores the possibility of using autologous MSCs as an IPF therapy and present an attempt to determine if the disease occurring in the lungs can be reflected on peripheral blood immune status. MethodsComprehensive characterization of autologous adipose derived MSCs (aMSCs) from five IPF patients and five age and gender matched Healthy Controls (HC) was done using flow cytometry, Droplet Digital PCR (ddPCR), Multiplex Luminex xMAP technology and confocal microscopy. For assessing the self renewal capacity and osteogenic differentiation IncuCyte Live Cell Imaging technology was used. Multi-parameter quantitative flow cytometry of un-manipulated whole blood of another group of 15 IPF patients and 87 (30 age and gender matched) HC was used to analyze 110 peripheral phenotypes.ResultsThere are no differences between autologous aMSCs from IPF patients and HC in their stem cell properties, self renewal capacity, plasticity for osteogenic differentiation, secretome content, cell cycle inhibitor marker levels and mitochondrial health. IPF patients had altered peripheral blood immunophenotype including reduced B cells subsets, increased T cell subsets, and increased granulocytes among others demonstrating clear and significant differences.ConclusionsOur results indicate that there is no difference in aMSCs properties from IPF patients and HC, suggesting that autologous aMSCs may be an acceptable option for IPF therapy.Characterization of peripheral immune phenotype may be a valuable indicator for successful therapy, and for potentially staging the disease.
Sequencing of myeloma therapy: Finding the right path among many standards
Rajkumar, S. Vincent

Mayo Clinic

Hematological Oncology | June 9, 2021 | Volume: 39 | Issue: S1 | Pages: 68-72

10.1002/hon.2848 | PMID 34105809 Get It

Faculty Opinions recommendation of Bedside POCUS during ward emergencies is associated with improved diagnosis and outcome: an observational, prospective, controlled study.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739415584.793585893 Get It

Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis
Leighton, Jonathan A. , Pasha, Shabana F., Cusimano, Frank A. , Mookhoek, Aart , Rosty, Christophe , Pai, Reetesh K. , Pai, Reetesh K, Pai, Rish K. , Cusimano, Frank, Hagen, Catherine E. , Pai, R K , Rosty, Christophe , Casteele, Niels Vande , Pai, Reetesh K

Mayo Clinic

Inflammatory Bowel Diseases | June 9, 2021 | Volume: 28 | Issue: 4 | Pages: 539-546

10.1093/ibd/izab122 | PMID 34106256 Get It

Abstract Background Eosinophils have been implicated in the pathogenesis of ulcerative colitis and have been associated with disease course and therapeutic response. However, associations between eosinophil density, histologic activity, and clinical features have not been rigorously studied. Methods A deep learning algorithm was trained to identify eosinophils in colonic biopsies and validated against pathologists’ interpretations. The algorithm was applied to sigmoid colon biopsies from a cross-sectional cohort of 88 ulcerative colitis patients with histologically active disease as measured by the Geboes score and Robarts histopathology index (RHI). Associations between eosinophil density, histologic activity, and clinical features were determined. Results The eosinophil deep learning algorithm demonstrated almost perfect agreement with manual eosinophil counts determined by 4 pathologists (interclass correlation coefficients: 0.805–0.917). Eosinophil density varied widely across patients (median 113.5 cells per mm2, interquartile range 108.9). There was no association between eosinophil density and RHI (P = 0.5). Significant differences in eosinophil density were seen between patients with Montreal E3 vs E2 disease (146.2 cells per mm2 vs 88.2 cells per mm2, P = 0.005). Patients on corticosteroids had significantly lower eosinophil density (62.9 cells per mm2 vs 124.1 cells per mm2, P = 0.006). No association between eosinophil density and biologic use was observed (P = 0.5). Conclusions We developed a deep learning algorithm to quantify eosinophils in colonic biopsies. Eosinophil density did not correlate with histologic activity but did correlate with disease extent and corticosteroid use. Future studies applying this algorithm in larger cohorts with longitudinal follow-up are needed to further elucidate the role of eosinophils in ulcerative colitis.
Challenging the association of hepatitis C and pyoderma gangrenosum
Croitoru, David , Sibbald, Cathryn , Brooks, Stephanie G. , Piguet, Vincent , Croitoru, D , Sibbald, C , Piguet, V , Alavi, Afsáneh

Mayo Clinic

British Journal of Dermatology | June 9, 2021 | Volume: 185 | Issue: 5 | Pages: 1047-1048

10.1111/bjd.20566 | PMID 34105770 Get It

Announcing the Editorial Board Fellowship Program of the American Journal of Physiology-Lung Cellular and Molecular Physiology
Shimoda, Larissa A. , Bai, Chunxue , Bartlett, Nathan W. , Bastarache, Julie A. , Kuebler, Wolfgang M. , Prakash, Y. S. , Schmidt, Eric P. , Morty, Rory E. , Prakash, Y S , Feghali‐Bostwick, Carol A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | June 9, 2021 | Volume: 321 | Issue: 1 | Pages: L116-L118

10.1152/ajplung.00239.2021 Get It